Manfred Rüdiger, Ariceum Therapeutics CEO (Presseportal)
June 8, 2022 03:00 AM EDTUpdated 09:39 AM
Financing
Startups

Ger­man start­up jumps in­to the hot ra­dio­phar­ma space with a for­mer Ipsen com­pound as lead pro­gram

Tyler Patchen

News Reporter

Ra­dio­phar­ma­ceu­ti­cals are con­tin­u­ing to be­come a hot top­ic in bio­phar­ma, with com­pa­nies such as Se­quoia, No­var­tis and Bris­tol My­ers Squibb look­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times